ABIVAX presents its 2024 half-year results

On September 9, 2024, ABIVAX published its half-yearly accounts for the period from January 1 to June 30, 2024. These financial statements report equity of EUR 126,469,872, including a loss of EUR 81,637,778.

The financial statements were prepared by the Board of Directors on September 5, 2024, in accordance with IAS 34. ABIVAX has implemented internal controls to prevent errors and fraud, although significant weaknesses were noted, including a lack of documentation and qualified personnel, without however having an immediate significant impact on the financial statements.

No significant events requiring accounting changes have been identified, and the company has assured that it has taken into account all risks related to the situation in Ukraine. Climate and macroeconomic commitments are integrated into key accounting estimates.

ABIVAX confirmed that all financial transactions and consequences of the period were correctly recorded and reflected in the financial statements. The company also ensured compliance with applicable legal and regulatory standards.

Finally, cybersecurity incidents that could affect the financial statements have been reported, although no significant unauthorized access has been identified.